News25/Ratings12
News · 26 weeks80+11%
2026-03-012026-08-23
Mix2890d
- SEC Filings10(36%)
- Other9(32%)
- Insider4(14%)
- Analyst3(11%)
- Earnings1(4%)
- Leadership1(4%)
Latest news
25 items- PRLongeveron Appoints Nirav Jhaveri as Chief Financial OfficerMr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Chief Financial Officer ("CFO"), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped into the role following the retirement of the
- PROpus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) (the "Company"), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company’s 2021 Inducement Plan, as amended, as a material inducement to employment to three non-executive employees who were not previously employees or directors of the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted in the form of options
- SECSEC Form EFFECT filed by Opus Genetics Inc.EFFECT - Opus Genetics, Inc. (0001228627) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.SCHEDULE 13G/A - Opus Genetics, Inc. (0001228627) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.SCHEDULE 13G/A - Opus Genetics, Inc. (0001228627) (Subject)
- SECSEC Form S-3 filed by Opus Genetics Inc.S-3 - Opus Genetics, Inc. (0001228627) (Filer)
- SECSEC Form 10-Q filed by Opus Genetics Inc.10-Q - Opus Genetics, Inc. (0001228627) (Filer)
- SECOpus Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Opus Genetics, Inc. (0001228627) (Filer)
- PROpus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate UpdateOPGx-BEST1 Cohort 1 Topline Data Expected in Second Week of September 2026 Enrollment Completed in LCA5 Registrational Trial with Dosing Planned for Q4 2026 RDH12, MERTK and RHO Programs Advancing with Upcoming Initiation of Clinical Testing Cash Runway into 2029 Expected to Support Multiple Clinical Inflection Points and Opportunities for Priority Review Vouchers RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or "Opus Genetics"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced financial results
- PROpus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal DiseaseTopline six-month efficacy data expected by end of 2027 Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) program Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provided during review RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the last patient has been enrolled in its registrational Phase 3 clinical trial evalu
- ANALYSTTD Cowen initiated coverage on Opus GeneticsTD Cowen initiated coverage of Opus Genetics with a rating of Buy
- INSIDERPresident Yerxa Benjamin R sold $22,064 worth of shares (7,429 units at $2.97), decreasing direct ownership by 1% to 704,106 units (SEC Form 4) to satisfy withholding tax4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERChief Operating Officer Schachle Joseph K sold $13,653 worth of shares (4,644 units at $2.94), decreasing direct ownership by 2% to 291,440 units (SEC Form 4) (withholding tax)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERChief Executive Officer Magrath George sold $27,926 worth of shares (9,475 units at $2.95), decreasing direct ownership by 0.54% to 1,731,869 units (SEC Form 4) to satisfy tax liability4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERChief Financial Officer Gagnon Robert E. sold $22,942 worth of shares (7,783 units at $2.95), decreasing direct ownership by 1% to 584,375 units (SEC Form 4) to cover taxes4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SECSEC Form 144 filed by Opus Genetics Inc.144 - Opus Genetics, Inc. (0001228627) (Subject)
- SECSEC Form 144 filed by Opus Genetics Inc.144 - Opus Genetics, Inc. (0001228627) (Subject)
- PROpus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 ResultsRESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company", "Opus Genetics" or "Opus"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs. Opus expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial during the second week of September 2026, assuming all participants complete their assessments as scheduled. In addition, the Company plans to present the data at the annual EURETINA Congress
- PROpus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal DiseaseSuccessful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study designFDA indicates Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provided during reviewCompany expects to initiate Phase 3 dosing in 4Q 2026 RESEARCH TRIANGLE PARK, N.C., July 06, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or "Opus Genetics"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) in a Type B Rare Disease Evidence Princi
- PROpus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® IndexesRESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or "Opus Genetics"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the Company will be added as a member of the broad-market Russell 3000®, the Russell 2000® and the Russell Microcap® Indexes, effective when the U.S. market opens on June 29, 2026, as part of the June 2026 Russell indexes reconstitution. "We are pleased to be included in these Russell indexes, which provide validation of the progress we’re making in advancing our gene therapies for in
- ANALYSTRBC Capital Mkts initiated coverage on Opus Genetics with a new price targetRBC Capital Mkts initiated coverage of Opus Genetics with a rating of Outperform and set a new price target of $10.00
- SECSEC Form EFFECT filed by Opus Genetics Inc.EFFECT - Opus Genetics, Inc. (0001228627) (Filer)
- SECOpus Genetics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Opus Genetics, Inc. (0001228627) (Filer)
- SECOpus Genetics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Opus Genetics, Inc. (0001228627) (Filer)
- SECSEC Form S-3 filed by Opus Genetics Inc.S-3 - Opus Genetics, Inc. (0001228627) (Filer)
IRD FAQ
5 questionsWhere does IRD stock trade?
Opus Genetics Inc. (IRD) is listed on NASDAQ.What sector and industry is IRD in?
Opus Genetics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IRD?
Opus Genetics Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2026-07-29. Recent price targets range from $700.00 to $1600.00.What companies are similar to IRD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IRD side-by-side with any of them on Quantisnow.How can I track IRD on Quantisnow?
Quantisnow aggregates Opus Genetics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IRD to receive live email and push alerts on every new disclosure.